These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26758290)

  • 21. Teriflunomide for multiple sclerosis in real-world setting.
    Elkjaer ML; Molnar T; Illes Z
    Acta Neurol Scand; 2017 Nov; 136(5):447-453. PubMed ID: 28321835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE
    Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
    Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P;
    Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
    Confavreux C; Li DK; Freedman MS; Truffinet P; Benzerdjeb H; Wang D; Bar-Or A; Traboulsee AL; Reiman LE; O'Connor PW;
    Mult Scler; 2012 Sep; 18(9):1278-89. PubMed ID: 22307384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of teriflunomide based therapy in patients with relapsing multiple sclerosis: A meta-analysis of randomized controlled trials.
    Xu M; Lu X; Fang J; Zhu X; Wang J
    J Clin Neurosci; 2016 Nov; 33():28-31. PubMed ID: 27492048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ▼Teriflunomide for multiple sclerosis.
    Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
    Freedman MS; Wolinsky JS; Comi G; Kappos L; Olsson TP; Miller AE; Thangavelu K; Benamor M; Truffinet P; O'Connor PW;
    Mult Scler; 2018 Apr; 24(4):535-539. PubMed ID: 28304217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teriflunomide for the treatment of multiple sclerosis.
    Oh J; O'Connor PW
    Semin Neurol; 2013 Feb; 33(1):45-55. PubMed ID: 23709212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
    Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
    J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
    [No Abstract]   [Full Text] [Related]  

  • 31. [Teriflunomide for treatment of multiple sclerosis].
    Warnke C; Meyer Zu Hörste G; Menge T; Stüve O; Hartung HP; Wiendl H; Kieseier BC
    Nervenarzt; 2013 Jun; 84(6):724-31. PubMed ID: 23695001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M
    Mult Scler; 2024 Jun; 30(7):833-842. PubMed ID: 38619037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teriflunomide: a review of its use in relapsing multiple sclerosis.
    Garnock-Jones KP
    CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
    Zagmutt FJ; Carroll CA
    Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
    Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
    Front Immunol; 2021; 12():730342. PubMed ID: 34721394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
    Wiese MD; Rowland A; Polasek TM; Sorich MJ; O'Doherty C
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1025-35. PubMed ID: 23682862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R; Bergvall N; Tomic D; Sfikas N; Cutter G; Giovannoni G
    Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
    Gerschenfeld G; Servy A; Valeyrie-Allanore L; de Prost N; Cecchini J
    Mult Scler; 2015 Oct; 21(11):1476-7. PubMed ID: 26199352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.